anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Authority Citation

Framework collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 2,176
Current window 1,141-1,170
Pages 73
Rows per page 30
Framework: Authority Citationclear collectionreset all
18 30 60

Framework

1,141-1,170 of 2,176

filter-aware
178
Uses expert testimony to undermine the investment thesis of a turnaround.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
181
The slide uses a direct quote from a 'Longtime C-level executive' to undermine investor confidence in the CEO.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
184
The slide uses expert testimony to debunk the bull case of a potential acquisition.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
189
The slide uses highlighted text to emphasize key negative sentiment regarding Nevro's customer loyalty and future market position.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
195
Uses expert testimony to frame the company's pricing strategy as a terminal failure.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
201
Uses direct quotes from 'high volume implanters' to build credibility for the bearish thesis.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
203
The slide uses a series of testimonials to undermine the company's growth narrative.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
157
Uses expert and former employee testimonials to build a case against the company's cost structure.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
159
Uses pull-quotes as primary evidence to support the 'villain' critique of the target company's economic viability.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
161
The slide uses a historical precedent to frame current battery company claims as part of a recurring pattern of fraud.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
169
Uses external press citations to undermine the credibility of the target company's investors.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
63
The slide uses direct quotes to expose potential data omissions and competitive disadvantage.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
134
The slide uses a direct quote and an abstract excerpt to build credibility for the argument that GH therapy has negative metabolic consequences.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
136
The slide uses a 'two-hit' metaphor to describe the synergistic risk of the two medications.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
152
The slide uses direct quotes from a KOL to build a case against the safety of a drug (Vykat) in the PWS population.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
154
The slide uses direct quotes from pediatric endocrinologists to highlight safety concerns, specifically referencing the drug's potential to exacerbate existing cardiac risks in PWS patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
216
Uses direct quotes from interviews to undermine the value proposition of the target company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
253
The slide uses a quote to undermine the credibility of the company's clinical trial data by highlighting the difference between controlled trial environments and real-world application.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
254
The slide uses direct quotes to frame the problem of insurance access as a deliberate strategy of 'playing chicken' by insurers.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
269
The slide uses direct quotes from an Anthem VP to undermine the product's market viability.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
270
The slide uses highlighted text to emphasize key parts of the expert interview transcript.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
279
The slide uses highlighted quotes from a former senior medical affairs employee to undermine the commercial viability of Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
294
The slide uses direct quotes from a KOL to undermine the company's narrative of drug efficacy and market adoption.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
327
The slide uses a bolded summary paragraph at the top, followed by a detailed Q&A transcript with yellow highlighting on key quotes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
390
The slide highlights a negative expert opinion on a drug being repurposed for PWS.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
391
The slide uses a 'quote-sandwich' technique: a summary paragraph followed by verbatim Q&A transcripts with highlighted key phrases.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
392
The slide uses direct quotes and Q&A excerpts to build a case against the safety of the drug Vykat in the context of PWS treatment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
414
The slide uses Q&A transcript format to build credibility for the thesis that generic substitution is common practice among specialists.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
21
The slide uses expert testimony to debunk the market perception of Lasertec as 'Japan's ASML'.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · The StruggleLoop · Cost Of Inaction1 hit
31
The slide uses bulleted expert testimony to build a case against the reliability and adoption success of Lasertec's ACTIS tools at TSMC.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit